Please use this identifier to cite or link to this item:
https://dora.health.qld.gov.au/qldresearchjspui/handle/1/6137Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Peter J Gilbar | en |
| dc.contributor.author | Khageshwor Pokharel | en |
| dc.contributor.author | Hilda M Mangos | en |
| dc.date.accessioned | 2024-07-19T02:34:06Z | - |
| dc.date.available | 2024-07-19T02:34:06Z | - |
| dc.date.issued | 2020 | - |
| dc.identifier.citation | 2021 Jul;27(5):1275-1280. doi: 10.1177/1078155220967087 | en |
| dc.identifier.uri | https://dora.health.qld.gov.au/qldresearchjspui/handle/1/6137 | - |
| dc.description.abstract | Temozolomide (TMZ) is an oral alkylating agent principally indicated for neurological malignancies including glioblastoma (GBM) and astrocytoma. Most common side effects are mild to moderate, and include fatigue, nausea, vomiting, thrombocytopenia and neutropenia. Severe or prolonged myelosuppression, causing delayed treatment or discontinuation, is uncommon. Major haematological adverse effects such as myelodysplastic syndrome or aplastic anaemia (AA) have rarely been reported. | en |
| dc.relation.ispartof | Journal of Oncology Pharmacy Practice | en |
| dc.title | Temozolomide-induced aplastic anaemia: Case report and review of the literature | en |
| dc.type | Article | en |
| dc.identifier.doi | https://doi.org/10.1177/107815522096708 | - |
| dc.rights.holder | Darling Downs Hospital and Health Service (DDHHS) affiliated author: Peter J Gilbar | en |
| dc.identifier.risid | alma991472523502062 | - |
| item.openairetype | Article | - |
| item.fulltext | No Fulltext | - |
| item.grantfulltext | none | - |
| item.cerifentitytype | Publications | - |
| item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
| Appears in Sites: | Darling Downs HHS Publications | |
Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.